Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Eisai to Market Kyorin's Overactive Bladder Drug in China

publication date: Sep 30, 2009
Kyorin Pharmaceutical Co. has licensed the ex-Japan Asian rights of its overactive bladder treatment to Eisai Co. (TSE: 4523), a fellow Japanese pharma. Uritos® Tablets (imidafenacin) was discovered by Kyorin, which has marketed the product in Japan since 2007. Eisai will own marketing rights for China, India, Sri Lanka and ASEAN countries. Kyorin and Eisai will work together to get the product approved for sale in these countries. More details...


Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital